129 related articles for article (PubMed ID: 8461606)
1. Fibrinogen Osaka IV: a congenital dysfibrinogenemia found in a patient originally reported in relation to surgery, now defined to have an A alpha arginine-16 to histidine substitution.
Yamazumi K; Terukina S; Matsuda M; Kanbayashi J; Sakon M; Tsujinaka T
Surg Today; 1993; 23(1):45-50. PubMed ID: 8461606
[TBL] [Abstract][Full Text] [Related]
2. Fibrinogen Sapporo: dysfibrinogenemia characterized by the replacement of A alpha arginine-16 by histidine resulting in the delayed release of fibrinopeptide A by thrombin.
Asakura S; Terukina S; Yamazumi K; Matsuda M; Murayama H; Higuchi A; Musashi M; Sakurada K; Miyazaki T
Nihon Ketsueki Gakkai Zasshi; 1989 Sep; 52(6):1094-104. PubMed ID: 2588959
[TBL] [Abstract][Full Text] [Related]
3. Fibrinogen Seattle II: congenital dysfibrinogenemia with an Arg (A alpha 16)----his substitution.
Ebert RF; Schreiler WE; Bell WR
Thromb Res; 1986 Jul; 43(1):7-13. PubMed ID: 3726812
[TBL] [Abstract][Full Text] [Related]
4. [Fibrinogen Bern II: hereditary fibrinogen variant with amino acid substitution of arginine replaced by histidine in position 16 of the A alpha chain].
Rupp C; Sievi R; Furlan M; Beck EA
Schweiz Med Wochenschr; 1983 Oct; 113(40):1460-2. PubMed ID: 6648427
[TBL] [Abstract][Full Text] [Related]
5. Fibrinogen Milano IV, another case of congenital dysfibrinogenemia with an abnormal fibrinopeptide A release (A alpha 16 Arg----His).
Bögli C; Hofer A; Baudo F; Redaelli R; Furlan M
Haemostasis; 1992; 22(1):7-11. PubMed ID: 1521828
[TBL] [Abstract][Full Text] [Related]
6. Fibrinogen Mitaka II: a hereditary dysfibrinogen with defective thrombin binding caused by an A alpha Glu-11 to Gly substitution.
Niwa K; Yaginuma A; Nakanishi M; Wada Y; Sugo T; Asakura S; Watanabe N; Matsuda M
Blood; 1993 Dec; 82(12):3658-63. PubMed ID: 7903170
[TBL] [Abstract][Full Text] [Related]
7. [Functional analysis for dysfibrinogenemias, Toyama and Adachi, which have a mutation of Aalpha16Arg-->His (CGT-->CAT) with aberrant fibrinopeptide A release].
Soya K; Takezawa Y; Terasawa F; Okumura N
Rinsho Byori; 2012 Jun; 60(6):499-505. PubMed ID: 22880226
[TBL] [Abstract][Full Text] [Related]
8. A new congenital abnormal fibrinogen Ise characterized by the replacement of B beta glycine-15 by cysteine.
Yoshida N; Wada H; Morita K; Hirata H; Matsuda M; Yamazumi K; Asakura S; Shirakawa S
Blood; 1991 May; 77(9):1958-63. PubMed ID: 2018836
[TBL] [Abstract][Full Text] [Related]
9. Fibrinogen Manchester: identification of an abnormal fibrinopeptide A with a C-terminal arginine leads to histidine substitution.
Southan C; Kehl M; Henschen A; Lane DA
Br J Haematol; 1983 May; 54(1):143-51. PubMed ID: 6849832
[TBL] [Abstract][Full Text] [Related]
10. Fibrinogen giessen I: a congenital homozygously expressed dysfibrinogenemia with A alpha 16 Arg----His substitution.
Alving BM; Henschen AH
Am J Hematol; 1987 Aug; 25(4):479-82. PubMed ID: 3618591
[TBL] [Abstract][Full Text] [Related]
11. Fibrinogen Kawaguchi: an abnormal fibrinogen characterized by defective release of fibrinopeptide A.
Matsuda M; Saeki E; Kasamatsu A; Nakamikawa C; Manabe S; Samejima Y
Thromb Res; 1985 Feb; 37(3):379-90. PubMed ID: 3992527
[TBL] [Abstract][Full Text] [Related]
12. Fibrinogen Barcelona II: a new case of A alpha 16 Arg----His substitution.
Borrell M; Vila L; Solá J; Coll I; Fontcuberta J
Haemostasis; 1990; 20(1):1-7. PubMed ID: 2323678
[TBL] [Abstract][Full Text] [Related]
13. Fibrinogen Kiel: a congenital dysfibrinogenaemia with (A alpha-16 Arg----His) substitution characterized by HPLC without prior isolation of fibrinogen.
Seydewitz HH; Gram J; Bruhn HD; Witt I
Blood Coagul Fibrinolysis; 1991 Aug; 2(4):501-6. PubMed ID: 1768762
[TBL] [Abstract][Full Text] [Related]
14. Fibrinogen Ledyard (A alpha Arg16----Cys): biochemical and physiologic characterization.
Lee MH; Kaczmarek E; Chin DT; Oda A; McIntosh S; Bauer KA; Clyne LP; McDonagh J
Blood; 1991 Oct; 78(7):1744-52. PubMed ID: 1912564
[TBL] [Abstract][Full Text] [Related]
15. Fibrinogen Claro--another dysfunctional fibrinogen variant with gamma 275 arginine-->histidine substitution.
Steinmann C; Jungo M; Beck EA; Lämmle B; Furlan M
Thromb Res; 1996 Jan; 81(1):145-50. PubMed ID: 8747529
[No Abstract] [Full Text] [Related]
16. Novel structure elucidation strategy for genetically abnormal fibrinogens with incomplete fibrinopeptide release as applied to fibrinogen Schwarzach.
Henschen A; Kehl M; Deutsch E
Hoppe Seylers Z Physiol Chem; 1983 Dec; 364(12):1747-51. PubMed ID: 6667926
[TBL] [Abstract][Full Text] [Related]
17. Two cases of dysfibrinogenemia characterized by abnormal FPB release: fibrinogen Madrid I & II.
Borrell M; Vila L; Solá J; Coll I; Gómez N; González N; Rutllant ML
Thromb Res; 1987 Mar; 45(5):591-9. PubMed ID: 3109061
[TBL] [Abstract][Full Text] [Related]
18. Fibrinogen Magdeburg I: a novel variant of human fibrinogen with an amino acid exchange in the fibrinopeptide A (Aalpha 9, Leu-->Pro).
Meyer M; Kutscher G; Stürzebecher J; Riesener G; Lutze G
Thromb Res; 2003 Jan; 109(2-3):145-51. PubMed ID: 12706644
[TBL] [Abstract][Full Text] [Related]
19. Fibrinogens Kawaguchi and Osaka: an amino acid substitution of A alpha arginine-16 to cysteine which forms an extra interchain disulfide bridge between the two A alpha chains.
Miyata T; Terukina S; Matsuda M; Kasamatsu A; Takeda Y; Murakami T; Iwanaga S
J Biochem; 1987 Jul; 102(1):93-101. PubMed ID: 3667568
[TBL] [Abstract][Full Text] [Related]
20. Thrombin hydrolysis of an N-terminal peptide from fibrinogen Lille: kinetic and NMR studies.
Zheng Z; Ashton RW; Ni F; Scheraga HA
Biochemistry; 1992 May; 31(18):4426-31. PubMed ID: 1581297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
